Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Rating) major shareholder Perceptive Advisors Llc purchased 25,200 shares of Soleno Therapeutics stock in a transaction dated Friday, May 19th. The shares were purchased at an average cost of $4.62 per share, for a total transaction of $116,424.00. Following the transaction, the insider now owns 1,889,655 shares in the company, valued at approximately $8,730,206.10. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Perceptive Advisors Llc also recently made the following trade(s):
- On Monday, May 22nd, Perceptive Advisors Llc acquired 27,300 shares of Soleno Therapeutics stock. The stock was purchased at an average cost of $5.12 per share, with a total value of $139,776.00.
Soleno Therapeutics Stock Up 2.5 %
SLNO stock opened at $5.40 on Wednesday. The stock has a market cap of $44.11 million, a price-to-earnings ratio of -1.73 and a beta of 0.21. Soleno Therapeutics, Inc. has a fifty-two week low of $0.85 and a fifty-two week high of $5.56. The business has a 50 day moving average price of $3.20 and a 200 day moving average price of $2.28.
Institutional Investors Weigh In On Soleno Therapeutics
Hedge funds have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP purchased a new position in Soleno Therapeutics in the first quarter worth $64,000. Millennium Management LLC acquired a new position in shares of Soleno Therapeutics during the 4th quarter worth $91,000. Renaissance Technologies LLC increased its holdings in shares of Soleno Therapeutics by 10.7% in the 4th quarter. Renaissance Technologies LLC now owns 49,754 shares of the company’s stock valued at $99,000 after purchasing an additional 4,800 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Soleno Therapeutics by 1,164,483.3% in the first quarter. JPMorgan Chase & Co. now owns 69,875 shares of the company’s stock valued at $150,000 after purchasing an additional 69,869 shares during the period. Finally, Clayton Partners LLC purchased a new stake in Soleno Therapeutics during the third quarter worth about $167,000.
Wall Street Analyst Weigh In
Separately, Oppenheimer reaffirmed an “outperform” rating and set a $8.00 price objective on shares of Soleno Therapeutics in a research report on Friday, March 24th.
About Soleno Therapeutics
Soleno Therapeutics, Inc operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS).
Featured Articles
- Get a free copy of the StockNews.com research report on Soleno Therapeutics (SLNO)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
